Wiesinger HAR; Shah J; White A; Yoshida EM; Frohlich J; Sirrs S; Gill S; Byrne MF

Language: Spanish
References: 16
Page:
PDF size: 115.36 Kb.

Text Extraction

Background: The metabolic syndrome and non-alcoholic fatty liver disease are increasing at alarming rates. Aims: To determine the effect of HMG-CoA reductase inhibitors (statins) on elevated liver enzymes in patients with hyperlipidemia. Patients: Patients with AST above 60 U/L prior to or during treatment with statin therapy at a quaternary care lipid clinic were reviewed. Methods: A retrospective analysis was conducted. Patients were separated into two groups: Group 1 – elevated AST prior to statin therapy; and Group 2 – elevated AST during statin therapy. Results: Forty six patients with one or more measurements of AST ›60 U/L remained after exclusion criteria were applied. Ten of 13 (77%) group 1 patients had reduced AST levels after initiation of statin therapy. Thirty two of 33 patients (97%) in group 2 had transient AST elevations while on statin therapy; one patient had persistently elevated AST after initiation of treatment. There were no significant adverse events reported. Conclusion: Use of HMG-CoA reductase inhibitors in patients with elevated AST resulted in normalization of AST levels. HMG-CoA reductase inhibitors were safe in patients with mildly elevated AST. This may translate to use of HMG-CoA reductase inhibitors in diseases such as non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

REFERENCES

1. Farrell GC, CZ Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112.

2. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21.

3. Zieve FJ. The metabolic syndrome: diagnosis and treatment. Clinical Cornerstone 2004; 6(S3): S5-S13.

4. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.

5. Stats Canada. Canadian Community Health Survey 2004.

6. Kiyici M, Gulten M, Gurel S, Giray S, Doar E, Savci G, Adim SB, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003; 17: 713-18.

7. Hatzitolios A, Savopoulos C, Lazaraki G, Sidiropoulos I, Haritanti P, Lefkopoulos A, Karagiannopoulou G, et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004; 23: 131-4.

8. Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, Garcia-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipidemic, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006; 23: 11643-1647.

9. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, et al. Ursoeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464-7.

10. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999; 31: 384(Lett).

11. Chalasani, N. Statins and hepatotoxicity: focus on patients with fatty liver. Perspectives in Clinical Hepatology. 2005; 41: 690-5.

12. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122; 1649-57.

13. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681-90.

14. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128-33.

15. Chalsani N, Gorski CJ, Craven R, Hall SD, Galinsky R. The effects of transjugular intrahepatic portasystemic shunts on the activity of cytochrome p450 3A in subjects with cirrhosis. Hepatology 2001; 34: 1103-8.

16. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 126: 1287-92.